



Human medicines special areas

The Sector has five sections

Orphan Medicines
Paediatric Medicines
Scientific Advice
Scientific Support and Projects
SME Office

3 Presentation title (to edit, click View > Header and Footer)



Orphan medicines

Main activities

Assessment and coordination of

- procedures for the designation of orphan medicinal products
- review of orphan designation criteria at the time of marketing authorization

Support to the Committee for Orphan Medicinal Products (COMP)



Committee for Orphan Medicinal Products

31 members + Chairman

- 1 Member per Member State
- 3 representatives from patient groups
- 3 members proposed by the EMEA

COMP Responsible for:

- opinions on designation
- advising on general EU policies
- international co-operation

Support by agency 3 secretaries and 4 scientific

administrators
Presentation title (to edit, click View > Header and Footer)



Orphan designation

Procedure to recognise drugs intended for development for rare diseases

And

Provide incentives for their development and marketing



Criteria for designation


RARITY (prevalence not > 5 in 10,000) / Insufficient RETURN OF INVESTMENT


SERIOUSNESS


Life -threatening or chronically debilitating

ALTERNATIVE METHODS AUTHORISED

If satisfactory method exist the sponsor should establish that the product will be of significant benefit









Incentives (I)

Economic / marketing

- Fee reduction / exemption
 - Extended incentives for SMEs (post authorisation)
- Market exclusivity

Product development

Protocol assistance

Community marketing authorisation

National incentives (EC inventory)

11 Presentation title (to edit, click View > Header and Footer)




Incentives (II)

Fee reductions (50% market authorisation aplication, 100% protocol assistance, post authorisation)

10-year market exclusivity

- protection against
 - similar products (structure/mech of action) for
 - same indication



EUROPEAN MEDICINES AGENCY

Paediatric medicines

Main activities

- administrative and scientific secretarial support to the PDCO and its working groups
- paediatric investigation plans (PIP) waivers and deferrals
- verification of compliance with PIP
- coordination of and secretarial support to the European Network of Paediatric Research;



Paediatric Committee (PDCO)

- Members from National competent authorities (22+2)
- 5 Members from CHMP
- 6 members from health care professional and parent-patient groups
- Chair, vice chair and alternate members

15 Presentation title (to edit, click View > Header and Footer)



Objectives of the paediatric regulation


- Increase high quality, ethical research into medicines for children
- Increase availability of authorised medicines for children
- · Increase information on medicines
- Without unnecessary studies in children
- Without delaying authorisation for adults




Incentives from paediatric regulation

Reward for medicinal products with a Paediatric Investigation Plan (PIP)

Extension of Supplementary Protection Certificate by 6 months





EUROPEAN MEDICINES AGENCY


Scientific advice

- scientific advice (SA) and protocol assistance (PA) to sponsors during the phase of research and development of medicinal products;
- provision of advice on non-product specific scientific issues and guidance on the qualification of biomarkers and novel methodologies;
- administrative and scientific secretarial support to the CHMP Scientific Advice Working Party



Scientific advice working party

- Multidisciplinary Expert Group: Chairperson and 27 Members, who are experts from National Authorities or from University Clinics and Other Institutions.
- One member comes from the Committee for Advanced Therapies (CAT) and 3 Members from the Committee for Orphan Medicinal Products (COMP).
- The SAWP is supported by the SA Section: 10 medical doctors and pharmacists and 7 secretaries and administrative assistants





Scientific support and projects

Main activities

- scientific support and coordination of scientific networks/projects within the Agency
- coordination of scientific projects
- provision of Certification for Non Clinical aspects of ATMPs (advanced medicinal products)
- contribution to the ATMPs classification;
- business pipeline activities

23 Presentation title (to edit, click View > Header and Footer)



Small and medium size enterprises (SME) office

- assistance to SMEs through the provision of various services including (one stop shop)
- assignment of SME status,
- responding to queries,
- granting fee incentives,
- organisation of workshops and training sessions.
- Translation of product information
- Certification of quality and non-clinical data for ATM



